Atlas Trials

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Clinical trial NCT03154749 · COMPLETED

Trial details

NCT number
NCT03154749
Sponsor
Guangdong Provincial People's Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-Negative Breast Cancer
Start date
2016-09-01
Primary completion
2019-12-31
Enrollment
93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.